Molecular Partners (MLLCF) to Release Earnings on Thursday

Molecular Partners (OTCMKTS:MLLCF) will likely be announcing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.3910) per share for the quarter.

Molecular Partners Price Performance

Shares of Molecular Partners stock opened at $2.25 on Thursday. The firm’s 50-day moving average price is $2.80 and its two-hundred day moving average price is $3.40. Molecular Partners has a 1-year low of $2.25 and a 1-year high of $4.15.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.

Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.